OakChart

LENZ Therapeutics Inc

LENZHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

4.11+0.01 (0.24%)
2026-11-12 02:29 CET
Market cap
128.82 USD m
Revenue, TTM
12.36 USD m
Net income, TTM
-140.27 USD m
Free cash flow, TTM
-127.70 USD m
EPS diluted, TTM
-4.48
P/E
-
Compare

Price

LENZ against its 20, 50 and 200-day averages
2050200beatmiss
5.0010.0015.0020.0025.003.0M6.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LENZclose 4.1120-day 3.4050-day 3.87200-day 7.384.1152w low

87.2% under the 52-week high of 32.13 on 24 Nov 2025. 52-week low 2.80 on 2 Nov 2026. Last 15 sessions, 56.1% high to low

Volume 0.67× normal · the line is the 50-bar volume average

Profile

LENZ
52-week range, 4% of the way up
2.8032.13

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

IndexRUT
Employees152
IPOJun 25, 2021
Beta0.76
ATR, 14d0.36
Rel volume0.67
Short float26.02%
Insider own13.51%
Inst own78.23%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap129.13M
Enterprise Value-67.71M
Income-140.27M
Sales12.36M
Book/sh6.11
Cash/sh6.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees152
IPOJun 25, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S10.45
P/B0.67
P/C0.65
P/FCF-
EV/EBITDA-
EV/Sales-5.48
Quick Ratio11.39
Current Ratio11.66
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.48
EPS next Y-1.19
EPS next Q-0.75
EPS this Y-44.65%
EPS next Y71.09%
EPS next 5Y38.19%
EPS past 3/5Y39.53% 19.13%
Sales past 3/5Y- -
EPS Y/Y TTM-112.65%
Sales Y/Y TTM-29.38%
EPS Q/Q-68.45%
Sales Q/Q-72.93%
EarningsOct 28 AMC
EPS/Sales Surpr.-10.84% -19.44%

Ownership

Insider Own13.51%
Insider Trans-39.04%
Inst Own78.23%
Inst Trans-16.22%
ROA-66.72%
ROE-72.69%
ROIC-73.06%
Gross Margin80.21%
Oper. Margin-1211.17%
Profit Margin-1134.97%
SMA2020.84%
SMA506.26%
SMA200-44.32%
Trades-

Technical

Shs Outstand31.42M
Shs Float27.17M
Short Float26.02%
Short Ratio7.82
Short Interest7.07M
52W High32.13 -87.21%
52W Low2.80 46.79%
Volatility14.68% 10.38%
ATR (14)0.36
RSI (14)59.19
Beta0.76
Rel Volume0.67
Avg Volume903.75K
Volume605,924

Performance

Perf Week18.79%
Perf Month20.88%
Perf Quarter-10.65%
Perf Half Y-48.94%
Perf YTD-74.31%
Perf Year-84.46%
Perf 3Y-62.89%
Perf 5Y-93.00%
Perf 10Y-
Recom1.57
Target Price17.71
Prev Close4.10
Price4.11
Change %0.24%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 12, 2026DowngradePPiper SandlerOverweight → Neutral$12+192.0%
Apr 14, 2025ResumedPPiper SandlerOverweight$38 → $51+1,140.9%
Mar 18, 2025InitiatedTTD CowenBuy$60+1,359.9%
Sep 27, 2024InitiatedRRaymond JamesOutperform$37+800.2%
Aug 12, 2024InitiatedHH.C. WainwrightBuy$38+824.6%
Apr 15, 2024InitiatedWWilliam BlairOutperform
Apr 15, 2024InitiatedLLeerink PartnersOutperform$32+678.6%
Apr 10, 2024InitiatedCCitigroupBuy$34+727.3%
Mar 27, 2024InitiatedPPiper SandlerOverweight$28+581.3%
Feb 23, 2023DowngradeCCowenOutperform → Market Perform

Peers

Mkt cap
TickerCompanyMkt cap
IRDOpus Genetics Inc358.58M
TARSTarsus Pharmaceuticals Inc3.78B
ALDXAldeyra Therapeutics Inc39.32M
HROWHarrow Inc1.10B
OTLKOutlook Therapeutics Inc117.10M
OCULOcular Therapeutix Inc1.47B
EYPTEyePoint Inc30.74M
ABBVAbbvie Inc521.41B
BLCOBausch + Lomb Corp7.62B
GKOSGlaukos Corp14.63B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RA CAPITAL MANAGEMENT, L.P.10% OwnerOct 29 '26Sale3.362,718,6849,134,77857,559Nov 02 05:44 PM
George Jeffrey P.DirectorMar 27 '26Buy8.925,59249,8905,592Mar 30 08:47 AM
Schimmelpennink Evert B.President, CEO and SecretaryMar 27 '26Buy8.9528,089251,41177,289Mar 30 08:46 AM
Chevallard Daniel R.Chief Financial OfficerMar 27 '26Buy8.577,50064,27512,886Mar 30 08:46 AM
Olsson ShawnChief Commercial OfficerNov 17 '25Option Exercise2.0810,00020,80014,733Nov 19 07:02 PM
Olsson ShawnChief Commercial OfficerNov 17 '25Sale26.1010,000261,0224,733Nov 19 07:02 PM
SHAWN OLSSONOfficerNov 17 '25Proposed Sale25.6040,0001,024,000Nov 17 04:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • LENZ Therapeutics Misses As VIZZ Finally Inflects, But A Sales-Force Retreat And CEO Exit Recast The Story (Earnings Whispers) +8.72%
  • LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession (GlobeNewswire)
  • LENZ Must Show VIZZ's July Surge Was A Trend, Not A One-Month Blip (Earnings Whispers)
  • LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 (GlobeNewswire)
  • These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
  • LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ... (GuruFocus.com)
  • LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
  • LENZ Therapeutics Inc (LENZ) Q2 2026 Earnings Report Preview: What To Look For (GuruFocus.com)
  • LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 (GlobeNewswire)
  • LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ for the Treatment of Presbyopia (GlobeNewswire)
  • LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand (GlobeNewswire)
  • LENZ Therapeutics adds China partner for presbyopia drug VIZZ (Proactive)
  • LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ (LNZ100) in Greater China (GlobeNewswire)
  • LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-28-0.990-0.893-0.9903.384.207
2026Q22026-08-11-1.020-1.051-1.0175.492.387
2026Q12026-05-11-1.320-1.048-1.3231.901.767
2025Q42026-03-24-1.160-0.908-1.1551.593.087
2025Q32025-11-05-0.590-0.692-0.58512.504.647
2025Q22025-07-30-0.530-0.610-0.5315.000.717
2025Q12025-05-07-0.530-0.518-0.5310.000.006
2024Q42025-03-19-0.460-0.410-0.4600.000.007
2024Q32024-11-06-0.380-0.458-0.3760.000.007
2024Q22024-08-14-0.400-0.479-0.4000.000.006
2024Q12024-05-08-3.530-0.820-3.5290.000.004
2023Q42024-03-18-2.575-0.910-2.7660.000.001
2023Q22023-09-11-6.790-6.790-6.8240.000.003
2023Q12023-07-25-2.993--2.9990.00-6
2022Q42023-03-20-3.080-3.454-3.0900.000.006
2022Q32022-11-09-3.150-3.110-3.1300.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-17.150-13.076-8.5380.000.00
2022FY-12.880-12.902-12.8910.000.00
2023FY-7.846--35.7150.00-
2024FY-2.340-2.676-2.3390.000.00
2025FY-2.850-2.549-2.64519.0919.51
2026FY--4.122--14.80
2027FY--1.192--32.63
2028FY--0.673--66.59
2029FY--0.095--86.03
2030FY-0.663--123.41

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-047254.013.306.00
2026Q4S2026-10-297244.173.306.00
2026Q4S2026-10-287034.463.206.74
2026Q4S2026-10-267034.463.206.74
2026Q4S2026-10-207064.463.206.74
2026Q4S2026-10-167154.963.208.10
2026Q4S2026-10-127245.153.498.10
2026Q4S2026-08-127245.163.608.10
2026Q4S2026-07-267117.573.9013.20
2026Q4S2026-07-177237.573.9013.20
2026Q4S2026-07-107147.543.9013.20
2026Q4S2026-07-067147.713.9013.20
2026Q4S2026-07-027147.723.9013.25
2026Q4S2026-07-017147.723.9013.25

Estimate history

EPS, annual-0.013-8.241-8.538-12.891-35.715-2.339-2.85-4.4815
Period2019202020212022202320242025TTM
EPS, quarterly-0.376-0.46-0.531-0.531-0.585-1.155-1.323-1.017-0.986
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000019.08812.36
Period2019202020212022202320242025TTM
Sales, quarterly000512.51.5881.9015.4863.384
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual8.2978.2978.2878.3171.96927.51831.34531.421
Period2019202020212022202320242025MRQ
Shares, quarterly27.48127.51827.53628.528.58831.34531.35431.41731.421
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue12.3619.090.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.450.700.060.018.350.730.120.00
Gross Profit9.9118.38-0.06-0.01-8.35-0.73-0.120.00
Selling, General and Administrative Excl. Other159.60109.5258.5572.4197.2959.7113.380.03
Research and Development0.0018.6729.8059.5064.4437.939.120.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-149.69-91.14-58.61-72.43-105.64-60.44-13.50-0.03
Interest Expense0.000.000.000.000.000.000.040.08
Unusual Expense0.000.000.000.000.0010.3254.830.00
Net Income Before Taxes-140.27-81.62-49.77-70.15-101.05-70.76-68.37-0.11
Income Taxes0.010.500.00-0.180.000.000.000.00
Consolidated Net Income-140.27-82.13-49.77-69.97-101.05-70.76-68.37-0.11
Net Income From Continuing Operations-140.27-82.13-49.77-69.97-101.05-70.76-68.37-0.11
Net Income-140.27-82.13-49.77-69.97-101.05-70.76-68.37-0.11
EPS (Recurring)-4.46-2.85-2.34-35.71-12.89-7.67-3.61-0.01
EPS (Basic, Before Extraordinaries)-4.48-2.85-2.34-35.71-12.89-8.54-8.24-0.01
EPS (Diluted)-4.48-2.85-2.34-35.71-12.89-8.54-8.24-0.01
EBITDA-149.25-90.85-58.55-72.41-97.29-59.71-13.38-0.03
Non-Operating Income (Expense)9.429.518.842.284.590.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.899.915.031.0613.537.870.180.00
Price To Sales Ratio9.7624.15------
Gross Margin80.2196.31------
Operating Margin-1,211.17-477.46------
Net Margin-1,134.97-430.25------
Shares Outstanding31.4231.3427.521.978.328.298.308.30
Market Capitalization128.82128.82793.95102.69130.53487.52488.88-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue3.385.491.901.5912.505.000.000.00
Cost of Goods Sold Incl. D&A0.450.281.190.530.120.020.040.03
Gross Profit2.935.210.711.0612.384.98-0.04-0.03
Selling, General and Administrative Excl. Other35.8539.3844.8539.5331.2621.8416.8915.20
Research and Development0.000.000.000.003.799.065.825.87
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-32.92-34.17-44.13-38.46-18.89-16.86-16.93-15.22
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-30.97-31.91-41.49-35.89-16.70-14.41-14.62-12.65
Income Taxes0.000.000.000.000.000.500.000.00
Consolidated Net Income-30.97-31.92-41.49-35.90-16.70-14.91-14.62-12.65
Net Income From Continuing Operations-30.97-31.92-41.49-35.90-16.70-14.91-14.62-12.65
Net Income-30.97-31.92-41.49-35.90-16.70-14.91-14.62-12.65
EPS (Recurring)-0.99-1.02-1.32-1.16-0.59-0.53-0.53-0.46
EPS (Basic, Before Extraordinaries)-0.99-1.02-1.32-1.16-0.59-0.53-0.53-0.46
EPS (Diluted)-0.99-1.02-1.32-1.16-0.59-0.53-0.53-0.46
EBITDA-32.81-34.06-44.02-38.36-18.76-16.84-16.89-15.20
Non-Operating Income (Expense)1.952.262.652.572.192.442.312.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.133.534.322.912.742.252.561.63
Price To Sales Ratio9.768.3013.6726.0475.97164.60--
Gross Margin86.5894.9037.5666.9499.0099.62--
Operating Margin-972.75-622.89-2,321.67-2,422.10-151.10-337.14--
Net Margin-915.16-581.81-2,182.43-2,260.45-133.60-298.24--
Shares Outstanding31.4231.4231.3531.3428.5928.5027.5427.52
Market Capitalization128.82178.09286.89500.641,328.56824.97708.13793.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments292.35209.1465.79268.23376.9819.820.01
Short Term Receivables2.430.000.000.000.000.000.00
Inventories2.940.000.000.000.000.000.00
Other Current Assets3.702.771.457.144.761.290.00
Total Current Assets301.41211.9267.24275.37381.7421.100.01
Net Property, Plant & Equipment1.921.990.3728.2118.081.460.00
Total Investments and Advances0.000.000.0017.040.000.000.00
Intangible Assets--0.00--0.000.00
Other Assets2.541.402.761.292.170.000.00
Total Assets305.88215.3070.38321.90401.9922.560.01
Short Term Debt Incl. Current Port. of LT Debt0.470.570.144.040.000.002.21
Accounts Payable4.174.265.712.612.450.630.00
Other Current Liabilities16.555.5812.676.399.6931.420.02
Total Current Liabilities21.1910.4118.5113.0412.1432.052.22
Long Term Debt0.350.810.191.750.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.9910.820.000.320.00
Total Liabilities21.5411.2219.7025.6112.1432.362.22
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00143.390.005.7955.610.00
Common Equity284.34204.08-92.71296.29384.05-65.41-2.22
Total Shareholders Equity284.34204.0850.68296.29389.84-9.80-2.22
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity284.34204.0850.68296.29389.84-9.80-2.22
Total Liabilities & Stockholders Equity305.88215.3070.38321.90401.9922.560.01
Book Value Per Share9.077.42-47.0835.6246.34-7.88-0.27
Tangible Book Value Per Share9.077.42-47.0835.6246.34-7.88-0.27
Full-Time Employees15242612069--
Price to Book Ratio0.673.690.500.411.271.22-
Return on Assets-31.52-24.65-35.67-27.92-33.33-605.88-
Return on Equity-33.63-25.68-40.33-29.46-37.24--
Return on Invested Capital-28.85-24.29-137.54-33.91-18.15--
Quick Ratio14.0920.363.6321.1131.440.660.00
Current Ratio14.2320.363.6321.1131.440.660.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-140.27-82.13-49.77-69.97-101.05-70.76-68.37-0.11
Depreciation0.440.290.060.018.350.730.120.00
Other Funds (Non Cash)16.529.423.410.1611.9319.6757.820.08
Funds from Operations-123.32-72.42-46.30-69.79-80.77-50.35-10.43-0.03
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-4.313.25-13.099.41-7.21-2.501.710.01
Cash from Operating Activities-127.63-69.17-59.39-60.38-87.98-52.85-8.72-0.02
Capital Expenditures-0.07-0.83-0.47-0.03-6.59-5.74-1.540.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments9.83-74.84-154.01-29.59-235.270.000.000.00
Purchase of Investments-165.65-280.80-241.91-52.09-405.520.000.000.00
Sale Or Maturity of Investments175.48205.9687.9022.50170.250.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities9.76-75.67-154.48-29.62-241.86-5.74-1.540.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock123.02149.7583.5583.180.60417.1630.080.00
Repurchase of Common Pref Stock0.000.000.000.00-0.080.000.000.00
Sale of Common Pref Stock123.02149.7583.5583.180.68417.1630.080.00
Proceedsfrom Stock Options122.95148.6279.5182.980.66416.8430.080.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00115.45-2.480.000.310.000.00
Other Financing Activities Uses0.000.00-2.37-2.480.000.000.000.00
Cash from Financing Activities123.02149.75199.0080.700.60417.4730.080.00
Net Change in Cash5.154.91-14.87-9.30-329.25358.8819.81-0.02
Free Cash Flow-127.70-70.00-59.86-60.41-94.57-58.59-10.27-0.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments197.30220.00258.38292.35202.17209.63
Short Term Receivables2.612.142.442.430.000.00
Inventories4.764.123.502.940.950.00
Other Current Assets2.227.024.043.703.883.97
Total Current Assets206.90233.28268.37301.41207.00213.60
Net Property, Plant & Equipment1.061.521.721.922.102.13
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.791.792.452.541.601.60
Total Assets209.75236.60272.54305.88210.70217.33
Short Term Debt Incl. Current Port. of LT Debt0.460.450.440.470.490.48
Accounts Payable5.526.6510.934.174.322.85
Other Current Liabilities11.7710.1214.4416.5511.507.06
Total Current Liabilities17.7517.2125.8121.1916.3210.40
Long Term Debt0.000.120.240.350.460.57
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities17.7517.3326.0421.5416.7810.97
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity192.00219.26246.49284.34193.93206.37
Total Shareholders Equity192.00219.26246.49284.34193.93206.37
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity192.00219.26246.49284.34193.93206.37
Total Liabilities & Stockholders Equity209.75236.60272.54305.88210.70217.33
Book Value Per Share6.116.987.869.076.787.24
Tangible Book Value Per Share6.116.987.869.076.787.24
Full-Time Employees---152--
Price to Book Ratio0.670.721.012.366.434.20
Return on Assets-66.72-55.52-46.01-31.52-27.09-24.95
Return on Equity-72.69-59.21-49.71-33.63-28.78-26.25
Return on Invested Capital-16.13-14.55-16.82-12.61-8.59-7.21
Quick Ratio11.3913.3110.2614.0912.6320.54
Current Ratio11.6613.5510.4014.2312.6920.54

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-30.97-31.92-41.49-35.90-16.70-14.91
Depreciation0.110.110.110.110.120.02
Other Funds (Non Cash)4.494.344.423.272.691.96
Funds from Operations-26.37-27.47-36.96-32.52-13.88-12.94
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.06-11.253.38-0.505.301.43
Cash from Operating Activities-22.31-38.71-33.58-33.02-8.59-11.51
Capital Expenditures0.00-0.02-0.02-0.04-0.44-0.24
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments28.6637.7733.18-89.77-3.89-0.17
Purchase of Investments-9.10-7.37-16.06-133.11-56.31-58.29
Sale Or Maturity of Investments37.7645.1449.2343.3452.4158.12
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities28.6637.7533.16-89.81-4.33-0.41
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.400.01122.610.6026.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.400.01122.610.6026.49
Proceedsfrom Stock Options0.000.400.00122.560.0026.07
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.400.01122.610.6026.49
Net Change in Cash6.34-0.56-0.41-0.22-12.3214.57
Free Cash Flow-22.31-38.73-33.60-33.06-9.03-11.75

Revenue breakdown

License2025: 17.50M
Product2025: 1.59M
United States2025: 19.09M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3026.02%7.1M27.2M843.52K
2026-10-1533.48%9.1M27.2M793.76K
2026-09-3038.87%10.6M27.2M851.90K
2026-09-1539.12%10.6M27.2M882.51K
2026-08-3140.02%10.9M27.2M842.74K
2026-08-1441.20%11.2M27.2M887.72K
2026-07-3141.37%11.3M27.4M906.18K
2026-07-1543.35%11.9M27.4M867.22K
2026-06-3038.13%10.4M27.4M812.97K
2026-06-1537.93%10.4M27.4M911.91K
2026-05-2937.40%10.2M27.4M945.85K
2026-05-1540.56%11.1M27.4M939.61K
2026-04-3038.69%10.7M27.7M920.77K
2026-04-1534.19%9.5M27.7M1.02M
2026-03-3132.65%9.0M27.7M1.09M
2026-03-1334.81%9.6M27.6M981.51K
2026-02-2732.24%8.9M27.6M1.07M
2026-02-1330.54%8.4M27.6M1.10M
2026-01-3025.78%7.3M28.2M1.22M
2026-01-1530.98%8.7M28.2M1.19M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.901.300.0001210.000.936-0.0110.001
call5.000.000.100.101.34272.000.000.215-0.0140.002
call7.500.004.900.052.8652.000.000.130-0.0220.001
put2.500.000.050.144.42779.000.00-0.143-0.0360.001
put5.000.004.901.4529.66043.000.00-0.784-0.0140.002
put7.501.005.703.6112.4910.000.00-0.870-0.0210.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-04SCHEDULE 13GSEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-02SCHEDULE 13D/ASEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-27SCHEDULE 13GSEC
2026-10-21SCHEDULE 13G/ASEC
2026-09-08SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-06-26SCHEDULE 13GSEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-128-KCurrent report2026-06-12SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-12SEC
2026-04-27SCHEDULE 13GSEC
2026-04-08SCHEDULE 13GSEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10009.13M1
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03365.58K300
2026-020000
2026-010000
2025-120000
2025-11289.30K2261.02K1

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.13.33%
Alpha Wave Global, LP11.52%
Versant Venture Management, LLC8.47%
BlackRock, Inc.7.31%
Aberdeen Group plc4.94%
MILLENNIUM MANAGEMENT LLC4.81%
VANGUARD CAPITAL MANAGEMENT LLC3.50%
72 Investment Holdings, LLC3.25%
Squarepoint Ops LLC3.08%
Blue Owl Capital Holdings LP2.41%

Funds

Fund% owned
abrdn Healthcare Investors3.34%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.61%
Fidelity Growth Company Fund2.58%
iShares Russell 2000 ETF1.72%
abrdn Life Sciences Investors1.60%
PRIMECAP Odyssey Aggressive Growth Fund1.30%
Fidelity Series Growth Company Fund1.00%
Fidelity Growth Company K6 Fund1.00%
VANGUARD EXTENDED MARKET INDEX FUND0.81%
Fidelity Small Cap Index Fund0.72%

OakChart. LENZ. Cached 15 minutes.